Cdex (CDEX) 10-K 29 Jan 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Oct. 31, 2014	Jan. 21, 2015	Apr. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	CDEX INC
Entity Central Index Key	1173738
Current Fiscal Year End Date	-21
Entity Filer Category	Smaller Reporting Company
Document Type	10-K
Document Period End Date	31-Oct-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		69,452,958
Entity Public Float			$1,006,000
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Oct. 31, 2014	Oct. 31, 2013
Current assets:
Cash	$90,915	$98,967
Accounts receivable - net	6,935	23,573
Inventory - net	250,751	240,232
Deferred costs	19,078	9,108
Total current assets	367,679	371,880
Property and equipment - net	28,709	37,889
Patents - net	46,913	51,559
Other assets	1,399	1,504
Total assets	444,700	462,832
Current liabilities:
Accounts payable and accrued expenses	72,885	8,140
Deferred Revenue	67,000	72,985
Line of credit payable	135,288
Total current liabilities	275,173	81,125
Total liabilities	275,173	81,125
Commitments and contingencies
Stockholders' equity
Class A common stock - $.005 par value per share, 300,000,000 shares authorized and 69,452,958 outstanding at October 31, 2014 and 52,946,963 outstanding at October 31, 2013	347,263	264,732
Additional paid in capital	35,619,772	35,336,108
Accumulated deficit	-35,797,539	-35,219,164
Total stockholders' equity	169,527	381,707
Total liabilities and stockholders' equity	444,700	462,832
Preferred stock - undesignated - $.005 par value per share, 350,000 shares authorized and none outstanding
Stockholders' equity
Preferred stock
Preferred stock - Series A - $.005 par value per share, 150,000 shares authorized and 6,250 outstanding at October 31, 2014 and at October 31, 2013
Stockholders' equity
Preferred stock	$31	$31

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Oct. 31, 2014	Oct. 31, 2013
Stockholders' equity
Common stock, par value per share (in Dollars per Share)	$0.01	$0.01
Common stock, shares authorized (in Shares)	300,000,000	300,000,000
Common stock, shares outstanding (in Shares)	69,452,958	52,946,963
Preferred stock - undesignated [Member]
Stockholders' equity
Preferred stock, par value per share (in Dollars per Share)	$0.01	$0.01
Preferred stock, shares authorized (in Shares)	350,000	350,000
Preferred stock, shares outstanding (in Shares)	0	0
Preferred stock - Series A [Member]
Stockholders' equity
Preferred stock, par value per share (in Dollars per Share)	$0.01	$0.01
Preferred stock, shares authorized (in Shares)	150,000	150,000
Preferred stock, shares outstanding (in Shares)	6,250	6,250

STATEMENTS_OF_OPERATIONS

STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
STATEMENTS OF OPERATIONS [Abstract]
Revenue	$177,923	$526,706
Cost of revenue	54,121	127,109
Gross profit	123,802	399,597
Operating expenses:
Selling, general and administrative	527,074	1,027,418
Research and development	180,685	145,557
Total operating expenses	707,759	1,172,975
Loss from operations	-583,957	-773,378
Other income/(expenses):
Note discount amortization
Interest expense	-1,223
Other income/(expenses)	6,805	28,267
Total other income/(expense)	5,582	28,267
Net loss	($578,375)	($745,111)
Basic net loss per common share (in Dollars per Share)	($0.01)	($0.01)
Basic weighted average common shares outstanding (in Shares)	56,852,043	52,872,994

STATEMENT_OF_CHANGES_IN_STOCKH

STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Series A Preferred Stock [Member]	Class A Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Oct. 31, 2012	$731,442	$31	$261,846	$34,943,618	($34,474,053)
Beginning Balance (in Shares) at Oct. 31, 2012		6,250	52,369,517
Share-based compensation expense	438,249		3,219	435,030
Share-based compensation expense (in Shares)			643,950
Forgiveness of debt	-42,873		-333	-42,540
Forgiveness of debt (in Shares)			-66,504
Net loss	-745,111				-745,111
Ending balance at Oct. 31, 2013	381,707	31	264,732	35,336,108	-35,219,164
Ending Balance (in Shares) at Oct. 31, 2013		6,250	52,946,963
Share-based compensation expense	24,280		3,321	20,959
Share-based compensation expense (in Shares)			663,995
Warrant exchange offer	316,840		79,210	237,630
Shares issued in exercise of warrants (in Shares)			15,842,000
Valuation of warrants issued for lines of credit	25,075			25,075
Net loss	-578,375				-578,375
Ending balance at Oct. 31, 2014	$169,527	$31	$347,263	$35,619,772	($35,797,539)
Ending Balance (in Shares) at Oct. 31, 2014		6,250	69,452,958

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Cash flows from operating activities:
Net loss	($578,375)	($745,111)
Adjustments to reconcile net loss to cash used by operating activities:
Depreciation and amortization	24,038	31,192
Share-based compensation	24,280	415,458
Negotiated settlements on accounts payable		-42,872
Noncash interest expense	1,223
Changes in operating assets and liabilities:
Accounts receivable	16,638	4,740
Inventory	-10,519	-62,540
Prepaid expenses and other assets	4,275	-9,108
Current liabilities	66,600	-54,650
Net cash used by operating activities	-451,840	-462,891
Cash flows from investing activities:
Purchase of property and equipment	-10,212
Net cash used by investing activities	-10,212
Cash flows from financing activities:
Proceeds received under line of credit	145,000
Proceeds received under Warrant Exchange offer	309,000
Net cash provided by financing activities	454,000
Net decrease in cash	-8,052	-462,891
Cash, beginning of the year	98,967	561,858
Cash, end of the year	90,915	98,967
Supplemental Cash Flow Information [Abstract]
Liabilitites resolved through Warrant Exchange offer	7,840
Issuance of previously accrued common stock		$22,790

Organization_of_Business_and_B

Organization of Business and Basis of Presentation	12 Months Ended
	Oct. 31, 2014
Organization of Business and Basis of Presentation [Abstract]
Organization of Business and Basis of Presentation	1. Organization of Business and Basis of Presentation
	CDEX Inc. (“CDEX,” “we,” “us,” “our” or the “Company”) is a technology development company incorporated in the State of Nevada on July 6, 2001 with a corporate office and research and development facility in Tucson, Arizona.  Our Class A common stock is currently being traded on the OTCBB under the symbol "CDEX.OB." Our long term strategic plans focus on applying our patented and patents pending chemical detection technologies to develop products in various markets including the healthcare, security and brand protection markets, as addressed below:
	1.           Healthcare - Validation of medications, training and quality assurance (e.g., validation of prescription and compounded medications to provide for patient safety, training of medical staff regarding compounding practices and detection of the diversion of narcotics and controlled substances);
	2.           Security and Public Safety - Identification of substances of concern (e.g., explosives, illegal drugs and the detection of counterfeit drugs and medications to assist in the protection of the nation's drug supply); and
	3.           Brand Protection - Detection of counterfeit or sub-par products for brand protection (e.g., inspection of incoming raw materials, outgoing final products and products in the distribution channel).
	The Company is also exploring unique opportunities in select market verticals where its proprietary technology may provide low cost/real time solutions to a growing concern such as conducting urine, blood and saliva analysis for detecting illegal drugs and performance enhancement substances.
	Virtually all CDEX product development has been based on applying the same underlying technologies. CDEX anticipates developing and/or acquiring other technologies in the future through partnering and investment. However, unless and until such time as we acquire or develop other technology assets, all of the Company's revenues will come from products developed from our current suite of patents and patents pending technologies, or through licensing arrangements with companies with related intellectual property.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Oct. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies
	Revenue Recognition
	Sales revenues are recognized when persuasive evidence of an agreement with the customer exists, products are shipped and installation, if necessary, completed, title passes pursuant to the terms of the agreement with the customer, the amount due from the customer is fixed or determinable, collectability is reasonably assured and there are no significant future performance obligations. Service revenues are recognized at the time of performance. Service maintenance revenues are typically recognized ratably over the term of the agreement.  Deferred revenue represents amounts invoiced or received but not recognized as revenue if the above revenue recognition terms are not met.
	Allowance for Doubtful Accounts
	We maintain an allowance for doubtful accounts based on the expected collectability of our accounts receivable. We perform credit evaluations of significant customers and establish an allowance for doubtful accounts based on the aging of receivables, payment performance factors, historical trends and other information. In general, we reserve a portion of those receivables outstanding more than 90 days and 100% of those outstanding more than 120 days. We evaluate and revise our reserve on a monthly basis based on a review of specific accounts outstanding and our history of uncollectible accounts. As of fiscal the years ended October 31, 2013 and 2012 we had no allowance for doubtful accounts.
	Inventory
	Inventory is valued at the lower of actual cost based on a first-in, first-out basis, or market. Inventory includes the cost of component raw materials and manufacturing. Due to the nature of our inventory, we analyze inventory on an item-by-item basis for obsolescence. The changes to obsolescence reserve for the years ended October 31, 2014 and 2013 are as follows:
		Year Ended October 31,
		2014		2013
	Balance, beginning of the year	$	24,832	$	25,365
	Inventory obsolescence adjustments		182		(533	)
	Balance, end of the year	$	25,014	$	24,832
	Property and Equipment
	Property and equipment are recorded at historical cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from two to seven years. Depreciation expense was approximately $23,000 and $26,000 for the years ended October 31, 2014 and 2013, respectively.
	Beneficial Conversion Features
	The intrinsic value of a beneficial conversion feature inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the date the note is due using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the beneficial conversion feature is measured by comparing the effective conversion price, after considering the relative fair value of detachable instruments included in the financing transaction, if any, to the fair value of the common shares at the commitment date to be received upon conversion.
	Research and Development Costs
	Research and development costs include compensation for employees and contractors, rent, professional services, materials, lab equipment and disposals.
	Share-Based Payments
	Share-based compensation costs are recognized as a component of selling, general and administrative expense in the Statements of Operations. Compensation expense for share-based payment arrangements with our employees is based on the grant date fair value of awards. We apply the Black-Scholes option pricing model to determine the fair value of stock options and apply judgment in estimating key assumptions that are important elements in the model and in expense recognition, such as the expected stock-price volatility, expected stock option life, expected dividends and expected forfeiture rates. Restricted stock awards with performance based vesting provisions are expensed based on our estimate of achieving the specific performance criteria on a straight-line basis over the requisite service period. We perform periodic reviews of the progress of actual achievement against the performance criteria in order to reassess the likely vesting scenario and, when applicable, realign the expense associated with that outcome.
	For share-based payments to non-employee consultants, the fair value of the share-based consideration issued is typically used to measure the transaction, as management believes this to be a more reliable measure of fair value than the services received. We apply the Black-Scholes option pricing model to determine the fair value of stock options or warrants that are granted. Consideration for services rendered by non-employee consultants is generally measured at the fair value of the Company's common stock or stock options on the date that performance is complete.
	Patents
	The Company capitalizes the costs of obtaining patents when patents are granted. Patents are amortized over their useful lives, which is generally ten years.  Amortization expense relative to patents was approximately $5,000  for both fiscal 2014 and 2013.
	Income Taxes
	Deferred tax assets and liabilities are recognized currently for the future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets if it is more likely that such assets will not be realized. We consider all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance is needed for some portion or all of a net deferred tax asset. Judgment is used in considering the relative impact of negative and positive evidence. In arriving at these judgments, the weight given to the potential effect of negative and positive evidence is commensurate with the extent to which it can be objectively verified. We record a valuation allowance to reduce our deferred tax assets and review the amount of such allowance annually. When we determine certain deferred tax assets are more likely than not to be utilized, we will reduce our valuation allowance accordingly.
	As of October 31, 2014 and 2013, we did not recognize any assets or liabilities relative to uncertain tax positions, nor do we anticipate any significant unrecognized tax benefits will be recorded during the next 12 months.  Any interest or penalties related to unrecognized tax benefits is recognized in income tax expense. Since there are no unrecognized tax benefits as a result of tax positions taken, there are no accrued penalties or interest. We are subject to tax audits for our U.S. federal and certain state tax returns for tax years 2007 to 2014. Tax audits by their very nature are often complex and can require several years to complete.
	Fair Value Measurements
	The carrying amounts of items reflected in current assets and current liabilities, as well as notes payable, approximate their fair value due to the short-term nature of their underlying terms.
	Concentrations
	For fiscal 2014 and 2013, our revenues consisted of transactions with 15 and 24 customers, respectively.  In fiscal 2014, approximately 19% of our revenues were sourced to the cancellation fees paid by the a former client and 21% of our revenues were derived from ValiMed Maintenance fees from our distributor in Kuwait for ten ValiMed CCT units  In fiscal 2013, approximately 64% of our revenues were derived from our sale to our distributor in Kuwait for ten ValiMed CCT units and 12% was from our ValiMed Maintenance fees.
	At times, the Company maintains cash balances that exceed federally insured limits.  Our cash balances are maintained with financial institutions with high credit standing and accordingly, the Company does not believe that this results in any significant credit risk.
	Net Loss Per Common Share
	Basic net loss per share was determined by dividing the net loss by the weighted average number of common shares outstanding during each year. The effect of common stock equivalents is not considered as it would be anti-dilutive.
	Recently Issued Accounting Pronouncements
	The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company's results of operations, balance sheet or cash flow.

Inventory

Inventory	12 Months Ended
	Oct. 31, 2014
Inventory [Abstract]
Inventory	3. Inventory
	Inventory consisted of the following at October 31, 2014 and 2013:
		2014			2013
	Raw materials	$	223,464		$	170,444
	Finished goods		52,301			94,620
	Subtotal		275,765			265,064
	Obsolescence reserve		(25,014	)		(24,832	)
	Total inventory	$	250,751		$	240,232

Property_and_Equipment

Property and Equipment	12 Months Ended
	Oct. 31, 2014
Property and Equipment [Abstract]
Property and Equipment	4. Property and Equipment
	Property and equipment consisted of the following at October 31, 2013 and 2012:
		2014			2013
	Furniture, fixtures and leasehold improvements	$	2,931		$	2,931
	Equipment		605,007			594,795
	Leased equipment		70,654			70,654
			678,592			668,380
	Less: Accumulated depreciation		(649,883	)		(630,491	)
	Property and equipment - net	$	28,709		$	37,889

Patents

Patents	12 Months Ended
	Oct. 31, 2014
Patents [Abstract]
Patents	5. Patents
	Patents consisted of the following at October 31, 2014 and 2013:
		2014			2013
	Patents	$	100,000		$	100,000
	Less: Accumulated amortization		(53,087	)		(48,441	)
	Patents - net	$	46,913		$	51,559
	Future amortization expense for our patents for the next five fiscal years is as follows:
	Five-Year Projected Patent Amortization
	Fiscal Years Ending October 31,	Amount
	2015		4,100
	2016		3,618
	2017		3,192
	2018		2,817
	2019		2,485

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	12 Months Ended
	Oct. 31, 2014
Accounts Payable and Accrued Expenses [Abstract]
Accounts Payable and Accrued Expenses	6. Accounts Payable and Accrued Expenses
	Accounts payable and accrued expenses consisted of the following at October 31, 2013 and 2012:
		2014		2013
	Accounts payable	$	61,571	$	4,900
	Accrued compensation		3,430		625
	Legal fees		5,509		240
	Accrued payable to a distributor		2,375		2,375
		$	72,885	$	8,140

Income_Taxes

Income Taxes	12 Months Ended
	Oct. 31, 2014
Income Taxes [Abstract]
Income Taxes	7. Income Taxes
	The benefit from income taxes reflected in the accompanying financial statements, all of which is deferred, varies from the amounts that would have been computed using statutory rates as follows:
		2014			2013
	Federal income taxes at the maximum statutory rate	$	206,687		$	253,338
	State income taxes, net of federal tax effect		27,964			34,275
	Permanent differences		11,761			11,445
	Increase in valuation allowance		(246,412	)		(299,058	)
	Benefit from income taxes	$	-		$	-
	Deferred income taxes consisted of the following as of October 31, 2014 and 2013:
		2014			2013
	Stock-based compensation	$	535,893		$	526,521
	Fixed asset basis difference		74,534			76,826
	Receivables excluded from income for income
	tax reporting purposes		2,677			9,099
	Accounts payable and accrued expenses deducted for financial
	statement purposes, but not for income tax reporting		28,134			3,142
	Net operating loss carryforwards		8,413,676			8,207,282
	Deferred tax asset		9,054,914			8,822,870
	Valuation allowance		(9,054,914	)		(8,822,870	)
	Total	$	-		$	-
	For income tax purposes, the Company has net operating loss carryforwards of approximately $21.8 million at October 31, 2014 that, subject to applicable limitations, may be applied against future taxable income. If not utilized, the net operating loss carryforwards will expire between 2024 and 2028.

ShareBased_Payments

Share-Based Payments	12 Months Ended
	Oct. 31, 2014
Share-Based Payments [Abstract]
Share-Based Payments	8. Share-Based Payments
	Stock Options and Stock Grants
	The Company has a 2002 Stock Incentive Plan, a 2003 Stock Incentive Plan and a 2013 Equity Incentive Plan (the “Plans”) (and the “2013 Plan”). Both the 2002 Plan and the 2003 Plan have terminated and all future equity incentive issuances will be charged to the 2013 Plan. The Plans provide for the issuance of stock options and stock grants.  The 2013 Plan permits the issuance of up to 75,000,000 shares through April 19, 2023. As of October 31, 2014, there are 73,900,055 shares available for grant from the 2013 Plan.
	.  No options were granted during the fiscal year ended October 31, 2014.  During the year ended October 31, 2013, the Company granted stock options for the purchase of 8,350,000 Class A Common Shares with an aggregate grant date fair value of $455,538.  We have a practice of issuing new stock to satisfy the exercises of stock options. Stock options were granted with an exercise price equal to the market price of the stock at the date of grant. Options granted were exercisable pursuant to vesting schedules from immediate to six years.
	During the year ended October 31, 2014, the Company awarded 970,955 restricted shares of Class A Common Shares to its members of its Board of Directors and contractors, including 92,165 shares to each of our external directors.  During the year ended October 31, 2013, the Company awarded 643,950 restricted shares of Class A Common Shares to its members of its Board of Directors, employees and contractors.  The restricted stock awards vest over six months and have an aggregate grant date fair value of $40,255.  We have a practice of issuing new stock to satisfy restricted stock grants. At October 31, 2014, there were no unrecognized compensation costs related to unvested restricted stock awards, and no unrecognized compensation costs related to unvested stock options.
	Stock option activity for fiscal years 2014 and 2013 under the Plan is as follows (the table retroactively reflects the 1 for 10 reverse stock split effective October 5, 2012):
								Weighted
					Weighted			Average
		Number of			Average			Remaining		Aggregate
		Shares			Exercise			Contractual		Intrinsic
		Issuable			Price			Term (Years)		Value
	Outstanding at October 31, 2012		910,500		$	0.5			4.4	$	-
	Options Granted		8,350,000		$	0.05
	Options Cancelled/Forfeited		(800,000	)	$	0.52
	Options Expired		(50,500	)	$	0.5
	Outstanding at October 31, 2013		8,410,000		$	0.05			4.2	$	83,500
	Options Expired		(15,000	)	$	0.1
	Outstanding at October 31, 2014		8,395,000		$	0.05			3.21	$	-
	Exercisable at October 31, 2014		8,395,000		$	0.05			3.21	$	-
	Total compensation expense related to stock awards for employees and consultants was $ 24,280 and $415,458 for the years ended October 31, 2014 and 2013, respectively.
	The fair value of restricted stock was estimated using the closing price of our Class A Common Stock on the date of award and fully recognized upon vesting.
	We determine the fair value of share-based awards at their grant date, using a Black-Scholes Option Pricing Model.  No options were issued during fiscal 2014 so those pricing assumptions in the following table are blank.  For options granted in fiscal year 2013, we estimated expected terms as being equal to the life of the grant. Actual compensation, if any, ultimately realized by option recipients may differ significantly from the amount estimated using an option valuation model.
		For the Year Ended October 31,
		2014		2013
	Weighted average grant date fair value	$              -		$           0.06
	Expected volatility	0%		75%
	Expected dividends	0%		0%
	Expected term (years)	-		5.00
	Risk free rate	-		0.77% - 0.79%
	Warrants
	In fiscal year 2014, warrants to purchase 13,975,815 shares of our Class A common stock were exercised under a warrant exchange offer including 2,000,000 warrant shares of Jason B. Terrell, our Medical Director and member of our Board of Directors, 500,000 warrant shares of Jeffrey K. Brumfield, our CEO and 250,000 warrant shares of Stephen A. McCommon, our CFO. Our Warrant Exchange Offer included an offer to all warrant holders with an exercise price of $0.10 per share an opportunity to exercise their warrants for $0.02 a share in exchange for the number of shares of common stock issuable under the warrant and a warrant for half the number of shares of common stock issuable under the exercised warrant with an exercise price of $0.15 a share.
	In fiscal year 2014, we issued warrants to purchase 6,987,908 shares of our Class A common stock under our warrant exchange offer including 1,000,000 warrant shares to Jason B. Terrell, 250,000 warrant shares to Jeffrey K. Brumfield and 125,000 warrant shares to Stephen A. McCommon.  We issued warrants to purchase 1,750,000 shares to PEMCO LLC and warrants to purchase 400,000 shares to Jeffrey K.  Brumfield, in connection with the creation of lines of credit, and warrants to purchase 779,604 shares of common stock under an original issuance agreement where we offered an opportunity to invest in the company for $0.02 a share and a warrant for half the number of shares of common stock purchased with an exercise price of $0.15 a share. We also issued warrants to purchase 153,500 shares of common stock as consultant compensation.
	As a part of the Bankruptcy plan discussed in note 11, all warrants were cancelled on the Plan effective date of October 5, 2012.  Warrants under the plan were issued subsequent to October 31, 2012.  In fiscal year 2013, the Company issued 41,295,142 shares and warrants to purchase 39,685,549 shares under the Plan in settlement of its obligations.  The following summarizes activity for fiscal years 2014 and 2013 for warrants to purchase our common stock:
							Weighted
					Weighted		Average
		Number of			Average		Remaining
		Shares			Exercise		Contractual
		Issuable			Price		Term (Years)
	Outstanding and exercisable at October 31, 2012		-		$	-
	Issued		40,509,552		$	0.19
	Outstanding at October 31, 2013		40,509,552		$	-
	Issued		10,071,012		$	0.17
	Exercise		(13,975,815	)	$	0.1
	Outstanding and exercisable at October 31, 2014		36,604,749		$	0.22	3.52

Notes_Payable

Notes Payable	12 Months Ended
	Oct. 31, 2014
Notes Payable [Abstract]
Notes Payable	9. Notes Payable
	Effective October 16, 2014, CDEX Inc. (the “Company”) entered into a Line of Credit Agreement with each of two lenders, one of whom is our CEO, Jeffrey K. Brumfield, and the other of which is a significant shareholder, PEMCO LLC.  The Line of Credit Agreements provide for the lenders to make available to the Company an aggregate amount of up to $430,000 in funding, upon which the Company may draw funds as needed at any time from the effective date until the maturity date which is March 31, 2015.  The Lines of Credit are secured by all assets of the Company. Pursuant to each Line of Credit Agreement, the Company has issued each lender a Revolving Note (collectively, the “Notes”) evidencing the net amount drawn by the Company during term of the Line of Credit Agreement.  The Notes bear interest at a rate of 12% per annum.  Interest on the balance of the Notes accrues and is payable on the first day of each month beginning on November 1, 2014.  On the maturity date, the Company must pay to the lenders an amount equal to 110% of the principal due on the Notes plus any accrued and unpaid interest as of that date.  The Company may prepay any principal balance on the Notes, but it must still pay 110% of such principal amount when paid.  As additional incentive for the lenders to enter into the Line of Credit Agreements and make available to the Company funds thereunder, the Company has issued to the lenders Warrants to purchase up to 2,150,000 shares of the Company’s Class A common stock in the aggregate.  The Warrants are exercisable for a period of five years at an exercise price of $0.25 per share.  The following reconciles notes payable as of October 31, 2014 and 2013:
		2014			2013
	Line of credit - PEMCO LLC - 12% interest payable monthly - matures		105,173			-
	March 31, 2015
	Line of credit - Jeffrey K Brumfield - 12% interest payable monthly - matures		40,039			-
	March 31, 2015
	Recognition of 10% bonus interest on lines of credit draws		14,500
	Recognition of warrant value on lines of credit		(25,075	)
	Amortization of warrant value on lines of credit		651
	Total lines of credit

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Oct. 31, 2014
Stockholders' Equity [Abstract]
Stockholders' Equity	10. Stockholders’ Equity
	In fiscal year 2014, we issued 13,975,815 shares of our Class A common stock under a warrant exchange offer including 2,000,000 shares to Jason B. Terrell, our Medical Director and member of our Board of Directors, 500,000 shares to Jeffrey K. Brumfield, our CEO and 250,000 shares to Stephen A. McCommon, our CFO.  . Our Warrant Exchange Offer included an offer to all warrant holders with an exercise price of $0.10 per share an opportunity to exercise their warrants for $0.02 a share in exchange for the number of shares of common stock issuable under the warrant and a warrant for half the number of shares of common stock issuable under the exercised warrant with an exercise price of $0.15 a share.  We also issued 970,995 shares of restricted stock as consultant compensation, including 92,165 shares to each of our external directors and we issued 1,640,815 shares in an original issuance transaction.
	During the three months ended January 31, 2012 a shareholder converted 425 shares of Preferred Stock Series A into 25,374 shares of Class A common stock.
	The financial statements for the fiscal year ended October 31, 2012 reflect the impact of Company’s Bankruptcy Plan going “effective” on October 5, 2012. As a part of the Plan, the Company underwent a 1 for 10 reverse stock split of its common stock. Additionally, as a part of the Plan approximately $3.5 million in liabilities, $116,000 of administrative financing and $700,000 were be resolved with the issuance of approximately 43 million shares of Series A common stock and warrants for approximately 43 million shares of Series A common stock.
	Due to administrative delays, the stock and warrants issued under the Plan were being issued after October 31, 2012.  In fiscal year 2013, the Company issued 41,295,142 shares and warrants to purchase 39,685,549 shares under the Plan in settlement of its obligations.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Oct. 31, 2014
Commitments and Contingencies [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies
	Operating Leases
	The Company leases approximately 3,000 square feet of office and laboratory space in Tucson, Arizona on a month-to-month basis. Monthly rent as of October 31, 2014 is approximately $2,000. Total rent expense was approximately $19,000 and $21,000 for the years ended October 31, 2014 and 2013, respectively.
	Litigation
	We may from time to time be involved in legal proceedings arising from the normal course of business. As of the date of this report, we have not received notice of any new legal proceedings.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Oct. 31, 2014
Selected Quarterly Financial Data (Unaudited) [Abstract]
Selected Quarterly Financial Data (Unaudited)	13. Selected Quarterly Financial Data (Unaudited)
	The following table summarizes the unaudited quarterly results of operations as reported for fiscal 2014 and 2013:
		Fiscal Year Ended October 31, 2014
		First			Second			Third			Fourth
		Quarter			Quarter			Quarter			Quarter
	Revenue	$	76,007		$	50,277		$	27,207		$	24,432
	Gross profit		56,342			44,038			19,685			3,737
	Income (loss) from operations		(122,240	)		(143,327	)		(125,553	)		(192,837	)
	Net income (loss)		(115,435	)		(143,327	)		(125,553	)		(194,060	)
	Basic and diluted net
	loss per common share		(0.002	)		(0.003	)		(0.002	)		(0.003	)
	Basic and diluted weighted
	average common
	shares outstanding		52,946,963			54,344,042			63,265,125			66,275,708
		Fiscal Year Ended October 31, 2013
		First			Second			Third			Fourth
		Quarter			Quarter			Quarter			Quarter
	Revenue	$	39,732		$	389,232		$	30,574		$	67,168
	Gross profit		23,184			336,079			4,819			35,515
	Loss from operations		(559,666	)		92,219			(175,768	)		(130,163	)
	Net loss		(561,616	)		122,104			(175,436	)		(130,163	)
	Basic and diluted net
	loss per common share		(0.01	)		0.002			(0.003	)		(0.002	)
	Basic and diluted weighted
	average common
	shares outstanding		52,686,021			52,924,937			52,934,055			52,946,963

Going_Concern

Going Concern	12 Months Ended
	Oct. 31, 2014
Going Concern [Abstract]
Going Concern	14. Going Concern
	The Company has incurred losses since its inception of approximately $35.8 million and has had limited product sales from its inception through fiscal 2014. The Company plans to raise cash to fund its operations and pay its outstanding obligations from credit facilities or the sale of its securities in the future. Nonetheless, there can be no guarantee that the Company will be able to raise cash or maintain its current workforce through any of these plans.
	The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company's ability to continue as a going concern and meet its obligations as they come due is dependent upon its ability to raise sufficient cash as discussed above. The Company's continued operations, as well as the implementation of our business plan, will depend upon its ability to raise additional funds through bank borrowings, equity or debt financing. The Company continues to seek prospective investors who may provide some of this funding. The Company also anticipates it will need to maintain its current workforce to achieve commercially viable sales levels. There can be no guarantee that these needs will be met or that sufficient cash will be raised to permit operations to continue. Should the Company be unable to raise sufficient cash to continue operations at a level necessary to achieve commercially viable sales levels, the liquidation value of the Company's assets may be substantially less than the balances reflected in the financial statements and the Company may be unable to pay its creditors. There is no assurance that the Company will succeed in these fund-raising efforts. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Subsequent_Events

Subsequent Events	12 Months Ended
	Oct. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events
	For the period subsequent to October 31, 2014, the date of our most recent balance sheet, through the date our financial statements were issued, the Company drew an additional $160,000 from its Lines of Credits leaving an available balance to draw upon of $125,000.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Oct. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Revenue Recognition, Policy	Revenue Recognition
	Sales revenues are recognized when persuasive evidence of an agreement with the customer exists, products are shipped and installation, if necessary, completed, title passes pursuant to the terms of the agreement with the customer, the amount due from the customer is fixed or determinable, collectability is reasonably assured and there are no significant future performance obligations. Service revenues are recognized at the time of performance. Service maintenance revenues are typically recognized ratably over the term of the agreement.  Deferred revenue represents amounts invoiced or received but not recognized as revenue if the above revenue recognition terms are not met.
Allowance for Doubtful Accounts, Policy	Allowance for Doubtful Accounts
	We maintain an allowance for doubtful accounts based on the expected collectability of our accounts receivable. We perform credit evaluations of significant customers and establish an allowance for doubtful accounts based on the aging of receivables, payment performance factors, historical trends and other information. In general, we reserve a portion of those receivables outstanding more than 90 days and 100% of those outstanding more than 120 days. We evaluate and revise our reserve on a monthly basis based on a review of specific accounts outstanding and our history of uncollectible accounts. As of fiscal the years ended October 31, 2013 and 2012 we had no allowance for doubtful accounts.
Inventory, Policy	Inventory
	Inventory is valued at the lower of actual cost based on a first-in, first-out basis, or market. Inventory includes the cost of component raw materials and manufacturing. Due to the nature of our inventory, we analyze inventory on an item-by-item basis for obsolescence. The changes to obsolescence reserve for the years ended October 31, 2014 and 2013 are as follows:
		Year Ended October 31,
		2014		2013
	Balance, beginning of the year	$	24,832	$	25,365
	Inventory obsolescence adjustments		182		(533	)
	Balance, end of the year	$	25,014	$	24,832
Property and Equipment, Policy	Property and Equipment
	Property and equipment are recorded at historical cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from two to seven years. Depreciation expense was approximately $23,000 and $26,000 for the years ended October 31, 2014 and 2013, respectively.
Beneficial Conversion Features, Policy	Beneficial Conversion Features
	The intrinsic value of a beneficial conversion feature inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the date the note is due using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the beneficial conversion feature is measured by comparing the effective conversion price, after considering the relative fair value of detachable instruments included in the financing transaction, if any, to the fair value of the common shares at the commitment date to be received upon conversion.
Research and Development Costs, Policy	Research and Development Costs
	Research and development costs include compensation for employees and contractors, rent, professional services, materials, lab equipment and disposals.
Share-Based Payments, Policy	Share-Based Payments
	Share-based compensation costs are recognized as a component of selling, general and administrative expense in the Statements of Operations. Compensation expense for share-based payment arrangements with our employees is based on the grant date fair value of awards. We apply the Black-Scholes option pricing model to determine the fair value of stock options and apply judgment in estimating key assumptions that are important elements in the model and in expense recognition, such as the expected stock-price volatility, expected stock option life, expected dividends and expected forfeiture rates. Restricted stock awards with performance based vesting provisions are expensed based on our estimate of achieving the specific performance criteria on a straight-line basis over the requisite service period. We perform periodic reviews of the progress of actual achievement against the performance criteria in order to reassess the likely vesting scenario and, when applicable, realign the expense associated with that outcome.
	For share-based payments to non-employee consultants, the fair value of the share-based consideration issued is typically used to measure the transaction, as management believes this to be a more reliable measure of fair value than the services received. We apply the Black-Scholes option pricing model to determine the fair value of stock options or warrants that are granted. Consideration for services rendered by non-employee consultants is generally measured at the fair value of the Company's common stock or stock options on the date that performance is complete.
Patents, Policy	Patents
	The Company capitalizes the costs of obtaining patents when patents are granted. Patents are amortized over their useful lives, which is generally ten years.  Amortization expense relative to patents was approximately $5,000  for both fiscal 2014 and 2013.
Income Taxes, Policy	Income Taxes
	Deferred tax assets and liabilities are recognized currently for the future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets if it is more likely that such assets will not be realized. We consider all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance is needed for some portion or all of a net deferred tax asset. Judgment is used in considering the relative impact of negative and positive evidence. In arriving at these judgments, the weight given to the potential effect of negative and positive evidence is commensurate with the extent to which it can be objectively verified. We record a valuation allowance to reduce our deferred tax assets and review the amount of such allowance annually. When we determine certain deferred tax assets are more likely than not to be utilized, we will reduce our valuation allowance accordingly.
	As of October 31, 2014 and 2013, we did not recognize any assets or liabilities relative to uncertain tax positions, nor do we anticipate any significant unrecognized tax benefits will be recorded during the next 12 months.  Any interest or penalties related to unrecognized tax benefits is recognized in income tax expense. Since there are no unrecognized tax benefits as a result of tax positions taken, there are no accrued penalties or interest. We are subject to tax audits for our U.S. federal and certain state tax returns for tax years 2007 to 2014. Tax audits by their very nature are often complex and can require several years to complete.
Fair Value Measurements, Policy	Fair Value Measurements
	The carrying amounts of items reflected in current assets and current liabilities, as well as notes payable, approximate their fair value due to the short-term nature of their underlying terms.
Concentrations, Policy	Concentrations
	At times, the Company maintains cash balances that exceed federally insured limits.  Our cash balances are maintained with financial institutions with high credit standing and accordingly, the Company does not believe that this results in any significant credit risk.
Net Loss Per Common Share, Policy	Net Loss Per Common Share
	Basic net loss per share was determined by dividing the net loss by the weighted average number of common shares outstanding during each year. The effect of common stock equivalents is not considered as it would be anti-dilutive.
Recently Issued Accounting Pronouncements, Policy	Recently Issued Accounting Pronouncements
	The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company's results of operations, balance sheet or cash flow.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Oct. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Schedule of Changes to Inventory Obsolescence Reserve	The changes to obsolescence reserve for the years ended October 31, 2014 and 2013 are as follows:
		Year Ended October 31,
		2014		2013
	Balance, beginning of the year	$	24,832	$	25,365
	Inventory obsolescence adjustments		182		(533	)
	Balance, end of the year	$	25,014	$	24,832

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Oct. 31, 2014
Inventory [Abstract]
Schedule of Inventory	Inventory consisted of the following at October 31, 2014 and 2013:
		2014			2013
	Raw materials	$	223,464		$	170,444
	Finished goods		52,301			94,620
	Subtotal		275,765			265,064
	Obsolescence reserve		(25,014	)		(24,832	)
	Total inventory	$	250,751		$	240,232

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Oct. 31, 2014
Property and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following at October 31, 2013 and 2012:
		2014			2013
	Furniture, fixtures and leasehold improvements	$	2,931		$	2,931
	Equipment		605,007			594,795
	Leased equipment		70,654			70,654
			678,592			668,380
	Less: Accumulated depreciation		(649,883	)		(630,491	)
	Property and equipment - net	$	28,709		$	37,889

Patents_Tables

Patents (Tables)	12 Months Ended
	Oct. 31, 2014
Patents [Abstract]
Schedule of Patents	Patents consisted of the following at October 31, 2014 and 2013:
		2014			2013
	Patents	$	100,000		$	100,000
	Less: Accumulated amortization		(53,087	)		(48,441	)
	Patents - net	$	46,913		$	51,559
Schedule of Patents, Future Amortization Expense	Future amortization expense for our patents for the next five fiscal years is as follows:
	Five-Year Projected Patent Amortization
	Fiscal Years Ending October 31,	Amount
	2015		4,100
	2016		3,618
	2017		3,192
	2018		2,817
	2019		2,485

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Oct. 31, 2014
Accounts Payable and Accrued Expenses [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following at October 31, 2013 and 2012:
		2014		2013
	Accounts payable	$	61,571	$	4,900
	Accrued compensation		3,430		625
	Legal fees		5,509		240
	Accrued payable to a distributor		2,375		2,375
		$	72,885	$	8,140

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Oct. 31, 2014
Income Taxes [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	Accounts payable and accrued expenses consisted of the following at October 31, 2013 and 2012:
		2014			2013
	Accounts payable	$	61,571		$	4,900
	Accrued compensation		3,430			625
	Legal fees		5,509			240
	Accrued payable to a distributor		2,375			2,375
		$	72,885		$	8,140
Schedule of Deferred Tax Assets and Liabilities	Deferred income taxes consisted of the following as of October 31, 2014 and 2013:
		2014			2013
	Stock-based compensation	$	535,893		$	526,521
	Fixed asset basis difference		74,534			76,826
	Receivables excluded from income for income
	tax reporting purposes		2,677			9,099
	Accounts payable and accrued expenses deducted for financial
	statement purposes, but not for income tax reporting		28,134			3,142
	Net operating loss carryforwards		8,413,676			8,207,282
	Deferred tax asset		9,054,914			8,822,870
	Valuation allowance		(9,054,914	)		(8,822,870	)
	Total	$	-		$	-

ShareBased_Payments_Tables

Share-Based Payments (Tables)	12 Months Ended
	Oct. 31, 2014
Share-Based Payments [Abstract]
Schedule of Share-Based Compensation, Stock Options Activity	Stock option activity for fiscal years 2014 and 2013 under the Plan is as follows (the table retroactively reflects the 1 for 10 reverse stock split effective October 5, 2012):
								Weighted
					Weighted			Average
		Number of			Average			Remaining		Aggregate
		Shares			Exercise			Contractual		Intrinsic
		Issuable			Price			Term (Years)		Value
	Outstanding at October 31, 2012		910,500		$	0.5			4.4	$	-
	Options Granted		8,350,000		$	0.05
	Options Cancelled/Forfeited		(800,000	)	$	0.52
	Options Expired		(50,500	)	$	0.5
	Outstanding at October 31, 2013		8,410,000		$	0.05			4.2	$	83,500
	Options Expired		(15,000	)	$	0.1
	Outstanding at October 31, 2014		8,395,000		$	0.05			3.21	$	-
	Exercisable at October 31, 2014		8,395,000		$	0.05			3.21	$	-
Schedule of Share-Based Payment Award, Stock Options Valuation Assumptions	For the Year Ended October 31,
		2014		2013
	Weighted average grant date fair value	$              -		$           0.06
	Expected volatility	0%		75%
	Expected dividends	0%		0%
	Expected term (years)	-		5.00
	Risk free rate	-		0.77% - 0.79%
Schedule of Share-Based Compensation, Warrant Activity	The following summarizes activity for fiscal years 2014 and 2013 for warrants to purchase our common stock:
							Weighted
					Weighted		Average
		Number of			Average		Remaining
		Shares			Exercise		Contractual
		Issuable			Price		Term (Years)
	Outstanding and exercisable at October 31, 2012		-		$	-
	Issued		40,509,552		$	0.19
	Outstanding at October 31, 2013		40,509,552		$	-
	Issued		10,071,012		$	0.17
	Exercise		(13,975,815	)	$	0.1
	Outstanding and exercisable at October 31, 2014		36,604,749		$	0.22	3.52

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
	Oct. 31, 2014
Notes Payable [Abstract]
Schedule of Components of Credit Balance Outstanding	The following reconciles notes payable as of October 31, 2014 and 2013:
		2014			2013
	Line of credit - PEMCO LLC - 12% interest payable monthly - matures		105,173			-
	March 31, 2015
	Line of credit - Jeffrey K Brumfield - 12% interest payable monthly - matures		40,039			-
	March 31, 2015
	Recognition of 10% bonus interest on lines of credit draws		14,500
	Recognition of warrant value on lines of credit		(25,075	)
	Amortization of warrant value on lines of credit		651
	Total lines of credit		135,288			-

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Oct. 31, 2014
Selected Quarterly Financial Data (Unaudited) [Abstract]
Schedule of Quarterly Financial Information	The following table summarizes the unaudited quarterly results of operations as reported for fiscal 2014 and 2013:
		Fiscal Year Ended October 31, 2014
		First			Second			Third			Fourth
		Quarter			Quarter			Quarter			Quarter
	Revenue	$	76,007		$	50,277		$	27,207		$	24,432
	Gross profit		56,342			44,038			19,685			3,737
	Income (loss) from operations		(122,240	)		(143,327	)		(125,553	)		(192,837	)
	Net income (loss)		(115,435	)		(143,327	)		(125,553	)		(194,060	)
	Basic and diluted net
	loss per common share		(0.002	)		(0.003	)		(0.002	)		(0.003	)
	Basic and diluted weighted
	average common
	shares outstanding		52,946,963			54,344,042			63,265,125			66,275,708
		Fiscal Year Ended October 31, 2013
		First			Second			Third			Fourth
		Quarter			Quarter			Quarter			Quarter
	Revenue	$	39,732		$	389,232		$	30,574		$	67,168
	Gross profit		23,184			336,079			4,819			35,515
	Loss from operations		(559,666	)		92,219			(175,768	)		(130,163	)
	Net loss		(561,616	)		122,104			(175,436	)		(130,163	)
	Basic and diluted net
	loss per common share		(0.01	)		0.002			(0.003	)		(0.002	)
	Basic and diluted weighted
	average common
	shares outstanding		52,686,021			52,924,937			52,934,055			52,946,963

Organization_of_Business_and_B1

Organization of Business and Basis of Presentation (Narrative) (Details)	12 Months Ended
	Oct. 31, 2014
Organization of Business and Basis of Presentation [Abstract]
Date of incorporation (Date)	6-Jul-01

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Narrative) (Details) (USD $)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Summary of Significant Accounting Policies [Abstract]
Allowance for doubtful accounts	$0	$0
Statement [Line Items]
Depreciation expense	23,000	26,000
Patents, useful lives (in Duration)	10 years
Patents, amortization expense	5,000	5,000
Assets or liabilities relative to uncertain tax positions	0	0
Significant unrecognized tax benefits	0	0
Accrued penalties or interest	$0	$0
Sales Revenue Net [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Number of customers participating in revenue transactions (in Customers)	15	24
Sales Revenue Net [Member] | Customer Concentration Risk [Member] | Former Client [Member]
Concentration Risk [Line Items]
Concentration risk (in Percent)	19.00%
Sales Revenue Net [Member] | Customer Concentration Risk [Member] | ValiMed Maintenance Fees Through Kuwait Distributor [Member]
Concentration Risk [Line Items]
Concentration risk (in Percent)	21.00%
Sales Revenue Net [Member] | Customer Concentration Risk [Member] | Kuwait Distributor [Member]
Concentration Risk [Line Items]
Concentration risk (in Percent)		64.00%
Number of client units (in Integer)	10
Sales Revenue Net [Member] | Customer Concentration Risk [Member] | ValiMed Maintenance Fees [Member]
Concentration Risk [Line Items]
Concentration risk (in Percent)		12.00%
Number of client units (in Integer)		10
Minimum [Member]
Statement [Line Items]
Property and equipment, estimated useful lives (in Duration)	2 years
Accounts Notes and Loans Receivable [Line Items]
Aging period of receivables partially reserved (in Duration)	90 days
Aging period of receivables reserved at 100%	120 days
Percent of receivables past due more than 120 days past due which are reserved (in Percent)	100.00%
Maximum [Member]
Statement [Line Items]
Property and equipment, estimated useful lives (in Duration)	7 years
Accounts Notes and Loans Receivable [Line Items]
Aging period of receivables partially reserved (in Duration)	120 days

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Schedule of Changes to Inventory Obsolescence Reserve) (Details) (USD $)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Summary of Significant Accounting Policies [Abstract]
Balance, beginning of the year	$24,832	$25,365
Inventory obsolescence adjustments	182	-533
Balance, end of the year	$25,014	$24,832

Inventory_Schedule_of_Inventor

Inventory (Schedule of Inventory) (Details) (USD $)	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2012
Inventory [Abstract]
Raw materials	$223,464	$170,444
Finished goods	52,301	94,620
Subtotal	275,765	265,064
Obsolescence reserve	-25,014	-24,832	-25,365
Total inventory	$250,751	$240,232

Property_and_Equipment_Schedul

Property and Equipment (Schedule of Property, Plant and Equipment) (Details) (USD $)	Oct. 31, 2014	Oct. 31, 2013
Property and Equipment [Abstract]
Furniture, fixtures and leasehold improvements	$2,931	$2,931
Equipment	605,007	594,795
Leased equipment	70,654	70,654
Total	678,592	668,380
Less: Accumulated depreciation	-649,883	-630,491
Property and equipment - net	$28,709	$37,889

Patents_Schedule_of_Finite_Liv

Patents (Schedule of Finite Lived Intangible Assets) (Details) (USD $)	Oct. 31, 2014	Oct. 31, 2013
Patents [Abstract]
Patents	$100,000	$100,000
Less: Accumulated amortization	-53,087	-48,441
Patents - net	$46,913	$51,559

Patents_Schedule_of_Finite_Liv1

Patents (Schedule of Finite Lived Intangible Assets, Future Amortization Expense) (Details) (USD $)	Oct. 31, 2014
Patents [Abstract]
2015	$4,100
2016	3,618
2017	3,192
2018	2,817
2019	$2,485

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Liabilities) (Details) (USD $)	Oct. 31, 2014	Oct. 31, 2013
Accounts Payable and Accrued Expenses [Abstract]
Accounts payable	$61,571	$4,900
Accrued compensation	3,430	625
Legal fees	5,509	240
Accrued payable to a distributor	2,375	2,375
Accounts payable and accrued expenses	$72,885	$8,140

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
	Oct. 31, 2014
Income Taxes [Abstract]
Net operating loss carryforwards subject to expiration	21,800,000
Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards expiration date (in Date)	20241231
Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards expiration date (in Date)	20281231

Income_Taxes_Schedule_of_Effec

Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details) (USD $)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Income Taxes [Abstract]
Federal income taxes at the maximum statutory rate	$206,687	$253,338
State income taxes, net of federal tax effect	27,964	34,275
Permanent differences	11,761	11,445
Increase in valuation allowance	-246,412	-299,058
Benefit from income taxes

Income_Taxes_Schedule_of_Defer

Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) (USD $)	Oct. 31, 2014	Oct. 31, 2013
Income Taxes [Abstract]
Stock-based compensation	$535,893	$526,521
Fixed asset basis difference	74,534	76,826
Receivables excluded from income for income tax reporting purposes	2,677	9,099
Accounts payable and accrued expenses deducted for financial statement purposes, but not for income tax reporting	28,134	3,142
Net operating loss carryforwards	8,413,676	8,207,282
Deferred tax asset	9,054,914	8,822,870
Valuation allowance	-9,054,914	-8,822,870
Total

ShareBased_Payments_Narrative_

Share-Based Payments (Narrative) (Details) (USD $)	12 Months Ended		3 Months Ended
	Oct. 31, 2014	Oct. 31, 2013	Jan. 31, 2012	Oct. 05, 2012
Share Based Compensation Arrangement by Share Based Payment Award [Line Items]
Share-Based Compensation Arrangement, Options granted (in Shares)		8,350,000
Ratio of reverse stock split applied retroactively to stock option activity table				10.00%
Share-based compensation	$24,280	$415,458
Class Of Warrant Or Right [Line Items]
Warrants issued (in Shares)	10,071,012	40,509,552
Class A Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Shares issued in exercise of warrants (in Shares)			-425
Class A Common Stock [Member] | Warrant Exchange Offer [Member]
Class Of Warrant Or Right [Line Items]
Shares issued in exercise of warrants (in Shares)	13,975,815
Percent of shares issuable which can be coverted to new exercise price (in Percent)	50.00%
Warrants issued (in Shares)	6,987,908
Class A Common Stock [Member] | Warrant Exchange Offer [Member] | Original Pre-Exchange Offer Exercise Price [Member]
Class Of Warrant Or Right [Line Items]
Warrant exercise price (in Dollars per Share)	$0.15
Class A Common Stock [Member] | Warrant Exchange Offer [Member] | Exchange Offer New Exercise Price [Member]
Class Of Warrant Or Right [Line Items]
Warrant exercise price (in Dollars per Share)	$0.02
Class A Common Stock [Member] | Warrant Exchange Offer [Member] | Medical Director [Member]
Class Of Warrant Or Right [Line Items]
Shares issued in exercise of warrants (in Shares)	2,000,000
Warrants issued (in Shares)	1,000,000
Class A Common Stock [Member] | Warrant Exchange Offer [Member] | Chief Executive Officer [Member]
Class Of Warrant Or Right [Line Items]
Shares issued in exercise of warrants (in Shares)	500,000
Warrants issued (in Shares)	250,000
Class A Common Stock [Member] | Warrant Exchange Offer [Member] | Chief Financial Officer [Member]
Class Of Warrant Or Right [Line Items]
Shares issued in exercise of warrants (in Shares)	250,000
Warrants issued (in Shares)	125,000
Class A Common Stock [Member] | Warrant Issuance For Lines Of Credit [Member] | Chief Executive Officer [Member] | Line of Credit [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in Shares)	400,000
Class A Common Stock [Member] | Warrant Issuance For Lines Of Credit [Member] | PEMCO LLC [Member] | Line of Credit [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in Shares)	1,750,000
Class A Common Stock [Member] | Warrant Original Issuance [Member]
Class Of Warrant Or Right [Line Items]
Percent of shares issuable which can be coverted to new exercise price (in Percent)	50.00%
Warrants issued for cash (in Shares)	779,604
Class A Common Stock [Member] | Warrant Original Issuance [Member] | Warrant Stated Exercise Price [Member]
Class Of Warrant Or Right [Line Items]
Warrant exercise price (in Dollars per Share)	$0.10
Class A Common Stock [Member] | Warrant Original Issuance [Member] | Exercise Price Offered For Number Of Shares Issuable With Warrant To Purchase Half The Shares Issuable At A Fifteen Cent Exercise Price [Member]
Class Of Warrant Or Right [Line Items]
Warrant exercise price (in Dollars per Share)	$0.02
Class A Common Stock [Member] | Warrant Original Issuance [Member] | Exercise Price Offered For Fity Percent Of Shares Purchasable With Warrant Issuable On Purchase Of Two Cent Per Share Exercise Of Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant exercise price (in Dollars per Share)	$0.15
Class A Common Stock [Member] | Warrants Issued For Consultant Compensation [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in Shares)	153,500
Class A Common Stock [Member] | Equity Issuance In Settlement Of Bankruptcy Plan Obligations [Member] | Bankruptcy Obligation Settlement [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in Shares)	39,685,549
Shares issued (in Shares)	41,295,142
Class A Common Stock [Member] | Equity Issuance In Settlement Of Bankruptcy Plan Obligations [Member] | Medical Director [Member]
Class Of Warrant Or Right [Line Items]
Shares issued in exercise of warrants (in Shares)	2,000,000
Class A Common Stock [Member] | Equity Issuance In Settlement Of Bankruptcy Plan Obligations [Member] | Chief Executive Officer [Member]
Class Of Warrant Or Right [Line Items]
Shares issued in exercise of warrants (in Shares)	500,000
Class A Common Stock [Member] | Equity Issuance In Settlement Of Bankruptcy Plan Obligations [Member] | Chief Financial Officer [Member]
Class Of Warrant Or Right [Line Items]
Shares issued in exercise of warrants (in Shares)	250,000
The 2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement by Share Based Payment Award [Line Items]
Stock incentive plan, shares authorized for issuance (in Shares)	75,000,000	75,000,000
Shares available for grant (in Shares)	73,900,055
Share-Based Compensation Arrangement, Options granted (in Shares)	0
Share-based compensation	24,280	415,458
The 2013 Equity Incentive Plan [Member] | Class A Common Stock [Member]
Share Based Compensation Arrangement by Share Based Payment Award [Line Items]
Share-Based Compensation Arrangement, Options granted (in Shares)		8,350,000
The 2013 Equity Incentive Plan [Member] | Class A Common Stock [Member] | Stock Options [Member]
Share Based Compensation Arrangement by Share Based Payment Award [Line Items]
Stock granted during the period, value		455,538
Unrecognized compensation costs related to unvested stock options	0
The 2013 Equity Incentive Plan [Member] | Class A Common Stock [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement by Share Based Payment Award [Line Items]
Stock granted during the period, value		40,255
Share-Based Compensation Arrangement, Options granted (in Shares)	970,955
Number of shares issued to each external director included in shares issued for services (in Shares)	92,165
Restricted shares granted to the Board of Directors (in Shares)		643,950
Restricted stock issued to independent directors, vesting period (in Duration)		6 months
Unrecognized compensation costs related to unvested restricted stock awards	$0

ShareBased_Payments_Schedule_o

Share-Based Payments (Schedule of Share-Based Compensation, Stock Options Activity) (Details) (USD $)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2012
Share Based Compensation Arrangement by Share Based Payment Award [Line Items]
Share-Based Compensation Arrangement, Options Outstanding, beginning of year (in Shares)	8,410,000	910,000
Share-Based Compensation Arrangement, Weighted Average Exercise Price, Options Outstanding, beginning of year (in Dollars per Share)	$0.05	$0.50
Share-Based Compensation Arrangement, Options granted (in Shares)		8,350,000
Share-Based Compensation Arrangement, Weighted Average Exercise Price, Options granted (in Dollars per Share)		$0.05
Share-Based Compensation Arrangement, Options cancelled/forfeited (in Shares)		-800,000
Share-Based Compensation Arrangement, Options cancelled/forfeited, Weighted Average Exercise Price (in Dollars per Share)		$0.52
Share-Based Compensation Arrangement, Options expired (in Shares)	15,000	-50,500
Share-Based Compensation Arrangement, Options expired, Weighted Average Exercise Price (in Dollars per Share)	$0.10	$0.50
Share-Based compensation arrangement, Options Outstanding, end of year (in Shares)	8,395,000	8,410,000	910,000
Share-Based Compensation Arrangement, Weighted Average Exercise Price, Options Outstanding, end of year (in Dollars per Share)	$0.05	$0.05	$0.50
Share-Based Compensation Arrangement, Weighted Average Remaining Contractual Term, Options Outstanding, end of year (in Duration)	3 years 2 months 16 days	4 years 2 months 12 days	4 years 4 months 24 days
Share-Based Compensation Arrangement, Aggregate Intrinsic Value, Options Outstanding, end of year		$83,500
Share-Based Compensation Arrangement, Options Exercisable, end of year (in Shares)	8,395,000
Share-Based Compensation Arrangement, Weighted Average Exercise Price, Options Exercisable, end of year (in Dollars per Share)	$0.05
Share-Based Compensation Arrangement, Weighted Average Remaining Contractual Term, Options Exercisable, end of year (in Duration)	3 years 2 months 16 days
Share-Based Compensation Arrangement, Aggregate Intrinsic Value, Options Exercisable, end of year

ShareBased_Payments_Schedule_o1

Share-Based Payments (Schedule of Share-Based Payment Award, Stock Options Valuation Assumptions) (Details) (USD $)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Share Based Compensation Arrangement by Share Based Payment Award [Line Items]
Weighted average grant date fair value (in Dollars per Share)		$0.06
Stock Options [Member]
Share Based Compensation Arrangement by Share Based Payment Award [Line Items]
Expected volatility (in Percent)	0.00%	75.00%
Expected dividends (in Percent)	0.00%	0.00%
Expected term (years) (in Duration)		5 years
Risk free rate (in Percent)
Stock Options [Member] | Minimum [Member]
Share Based Compensation Arrangement by Share Based Payment Award [Line Items]
Risk free rate (in Percent)		0.77%
Stock Options [Member] | Maximum [Member]
Share Based Compensation Arrangement by Share Based Payment Award [Line Items]
Risk free rate (in Percent)		0.79%

ShareBased_Payments_Schedule_o2

Share-Based Payments (Schedule of Share-Based Compensation, Warrant Activity) (Details) (USD $)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2012
Share-Based Payments [Abstract]
Warrants outstanding (in Shares)	36,604,749	40,509,552	0
Warrants issued (in Shares)	10,071,012	40,509,552
Exercise (in Shares)	-13,975,815
Weighted average exercise price of shares issuable with warrants outstanding and exercisable (in Dollars per Share)	$0.22	$0	$0
Weighted average exercise price of shares issuable with warrants issued (in Dollars per Share)	$0.17	$0.19
Weighted average exercise price of shares issued with warrants exercised (in Dollars per Share)	$0.10
Weighted average remaining contractual term of warrants outstanding and exercisable (in Duration)	3 years 6 months 7 days

Notes_Payable_Narrative_Detail

Notes Payable (Narrative) (Details) (USD $)	12 Months Ended		0 Months Ended
	Oct. 31, 2014	Oct. 31, 2013	Oct. 16, 2014
Line of Credit Facility [Line Items]
Line of credit, warrants issued as consideration (in Shares)	10,071,012	40,509,552
Line of Credit [Member] | Short Term Debt [Member] | CFO and PEMCO [Member]
Line of Credit Facility [Line Items]
Number of lenders (in Integer)			$2
Line of credit maximum borrowing capacity			$430,000
Line of credit maturity date (in Date)			31-Mar-15
Line of credit stated interest rate (in Percent)			12.00%
Line of credit, date of first required payment (in Date)			1-Nov-14
Line of credit, percent of principal due on maturity (in Percent)			110.00%
Line of credit, warrants issued as consideration (in Shares)			2,150,000
Term of warrants issued as consideration in obtaining line of credit (in Duration)			5 years
Warrant exercise price (in Dollars per Share)			$0.25

Notes_Payable_Schedule_of_Comp

Notes Payable (Schedule of Components of Credit Line Balance Outstanding) (Details) (USD $)	Oct. 31, 2014	Oct. 31, 2013	Jan. 31, 2014
Line of Credit Facility [Line Items]
Line of credit balance, components	$135,288
Line of Credit [Member] | Short Term Debt [Member]
Line of Credit Facility [Line Items]
Line of credit balance, components			135,288
Line of Credit [Member] | Short Term Debt [Member] | Recognition Of Ten Percent Bonus Interest On Lines Of Credit Draws [Member]
Line of Credit Facility [Line Items]
Line of credit balance, components			14,500
Line of Credit [Member] | Short Term Debt [Member] | Recognition Of Warrant Values On Lines Of Credit [Member]
Line of Credit Facility [Line Items]
Line of credit balance, components			-25,075
Line of Credit [Member] | Short Term Debt [Member] | Amortization Of Warrant Values On Lines Of Credit [Member]
Line of Credit Facility [Line Items]
Line of credit balance, components			651
Line of Credit [Member] | Short Term Debt [Member] | PEMCO LLC [Member]
Line of Credit Facility [Line Items]
Line of credit balance, components			105,173
Line of Credit [Member] | Short Term Debt [Member] | Chief Financial Officer [Member]
Line of Credit Facility [Line Items]
Line of credit balance, components			$40,039

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended
	Oct. 05, 2012	Jan. 31, 2012	Oct. 31, 2013	Oct. 31, 2014
Discharge of Debt [Member]
Fresh Start Adjustment [Line Items]
Other liabilities to be resolved under bankruptcy plan	$3,500,000
Administrative financing to be resolved under bankruptcy plan	116,000
Total claims	$700,000
Class A Common Stock [Member]
Class of Stock [Line Items]
Shares (converted) / issued in conversion of convertible securities		-425
Class A Common Stock [Member] | Exchange of Stock for Stock [Member]
Fresh Start Adjustment [Line Items]
Reverse stock split conversion ratio (in Percent)	$0.10
Class A Common Stock [Member] | Discharge of Debt [Member] | Per Initial Plan [Member]
Fresh Start Adjustment [Line Items]
Warrants issued in bankruptcy debt conversion (in Shares)	43,000,000
Shares issued in bankruptcy debt conversion (in Shares)	43,000,000
Class A Common Stock [Member] | Discharge of Debt [Member] | As Issued [Member]
Fresh Start Adjustment [Line Items]
Warrants issued in bankruptcy debt conversion (in Shares)			39,685,549
Shares issued in bankruptcy debt conversion (in Shares)			41,295,142
Class A Common Stock [Member] | Warrant Exchange Offer [Member]
Class of Stock [Line Items]
Shares (converted) / issued in conversion of convertible securities				13,975,815
Percent of shares issuable which can be coverted to new exercise price (in Percent)				50.00%
Class A Common Stock [Member] | Warrant Exchange Offer [Member] | Warrant Stated Exercise Price [Member]
Class of Stock [Line Items]
Warrant exercise price (in Dollars per Share)				0.1
Class A Common Stock [Member] | Warrant Exchange Offer [Member] | Exercise Price Offered For Number Of Shares Issuable With Warrant To Purchase Half The Shares Issuable At A Fifteen Cent Exercise Price [Member]
Class of Stock [Line Items]
Warrant exercise price (in Dollars per Share)				0.02
Class A Common Stock [Member] | Warrant Exchange Offer [Member] | Exercise Price Offered For Fity Percent Of Shares Purchasable With Warrant Issuable On Purchase Of Two Cent Per Share Exercise Of Warrants [Member]
Class of Stock [Line Items]
Warrant exercise price (in Dollars per Share)				0.15
Class A Common Stock [Member] | Warrant Exchange Offer [Member] | Medical Director [Member]
Class of Stock [Line Items]
Shares (converted) / issued in conversion of convertible securities				2,000,000
Class A Common Stock [Member] | Warrant Exchange Offer [Member] | Chief Executive Officer [Member]
Class of Stock [Line Items]
Shares (converted) / issued in conversion of convertible securities				500,000
Class A Common Stock [Member] | Warrant Exchange Offer [Member] | Chief Financial Officer [Member]
Class of Stock [Line Items]
Shares (converted) / issued in conversion of convertible securities				250,000
Restricted Stock [Member]
Class of Stock [Line Items]
Shares issued for services (in Shares)				970,995
Number of shares of stock issued during period shares issued for services issued to each external director (in Shares)				92,165
Preferred Class A [Member]
Class of Stock [Line Items]
Shares (converted) / issued in conversion of convertible securities		25,374

Commitments_and_Contingencies_

Commitments and Contingencies (Narrative) (Details) (USD $)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Commitments and Contingencies [Abstract]
Area of office and laboratory lease space (in Square feet)	3,000
Monthly rent expense	$2,000
Total rent expense	$19,000	$21,000

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Unaudited) (Schedule of Quarterly Financial Information) (Details) (USD $)	3 Months Ended								12 Months Ended
	Oct. 31, 2014	Jul. 31, 2014	Apr. 30, 2014	Jan. 31, 2014	Oct. 31, 2013	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2014	Oct. 31, 2013
Selected Quarterly Financial Data (Unaudited) [Abstract]
Revenue	$24,432	$27,207	$50,277	$76,007	$67,168	$30,574	$389,232	$39,732	$177,923	$526,706
Gross profit	3,737	19,685	44,038	56,342	35,515	4,819	336,079	23,184	123,802	399,597
Loss from operations	-192,837	-125,553	-143,327	-122,240	-130,163	-175,768	92,219	-559,666	-583,957	-773,378
Net loss	($194,060)	($125,553)	($143,327)	($115,435)	($130,163)	($175,436)	$122,104	($561,616)	($578,375)	($745,111)
Basic net loss per common share (in Dollars per Share)	($0.00)	($0.00)	($0.00)	($0.00)	($0.00)	($0.00)	$0.00	($0.01)	($0.01)	($0.01)
Basic weighted average common shares outstanding (in Shares)	66,275,708	63,265,125	54,344,042	52,946,963	52,946,963	52,934,055	52,924,937	52,686,021	56,852,043	52,872,994

Going_Concern_Narrative_Detail

Going Concern (Narrative) (Details) (USD $)	Oct. 31, 2014	Oct. 31, 2013
Going Concern [Abstract]
Accumulated deficit	($35,797,539)	($35,219,164)

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Details) (USD $)	12 Months Ended		3 Months Ended
	Oct. 31, 2014	Oct. 31, 2013	Jan. 29, 2015
Subsequent Event [Line Items]
Proceeds received under line of credit	$145,000
Line of Credit [Member]
Subsequent Event [Line Items]
Proceeds received under line of credit			160,000
Remaining borrowing capacity			$125,000

Uncategorized_Items

Uncategorized Items
[us-gaap_StockIssuedDuringPeriodSharesNewIssues]	1,640,815